No recommendation
No news or research item is a personal recommendation to deal. Hargreaves Lansdown may not share ShareCast's (powered by Digital Look) views.
(Sharecast News) - Ondine Biomedical announced the appointment of Michael Behlke as its chief financial and chief operating officer on Wednesday, strengthening its leadership team as the company advanced its commercialisation strategy.
The AIM-traded firm said Behlke would bring more than 30 years of financial and operational experience in the medical technology sector, having secured more than $250m in funding and facilitated acquisitions exceeding $700m.
Prior to joining Ondine, Behlke served as CFO and acting COO at Ventec Life Systems, where he oversaw the company's expansion from $13m to $500 million in annual revenue.
He reportedly played a key role in the company's partnership with General Motors to scale ventilator production for the US Strategic National Stockpile during the Covid-19 pandemic.
"Ondine is at a critical inflection point as we expand our hospital-based infection prevention solutions," said chief executive officer Carolyn Cross.
"Michael's extensive MedTech industry experience, operational leadership, and business transformation successes will be key to accelerating our worldwide commercialization efforts, initially within Canada, and the UK [and] EU, and then rapidly expanding into the US post-FDA approval."
In his new role at Ondine, the board said Behlke would oversee capital markets strategies, operational efficiency, and international expansion, ensuring the company was well-positioned for sustained growth and market leadership.
"I am honored to join Ondine at this pivotal moment," commented Michael Behlke.
"The company's groundbreaking photodisinfection technology represents a paradigm shift in infection control.
"I look forward to working with this talented team to drive operational excellence, financial growth, and global adoption of this life-saving technology."
Reporting by Josh White for Sharecast.com.
The value of investments can go down in value as well as up, so you could get back less than you invest. It is therefore important that you understand the risks and commitments. This website is not personal advice based on your circumstances. So you can make informed decisions for yourself we aim to provide you with the best information, best service and best prices. If you are unsure about the suitability of an investment please contact us for advice.
